Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer

Abstract Introduction According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)‐resistant mechanisms (liquid rebiopsy) for lu...

Full description

Bibliographic Details
Main Authors: Yen‐Ting Lin, Chao‐Chi Ho, Wei‐Hsun Hsu, Wei‐Yu Liao, Ching‐Yao Yang, Chong‐Jen Yu, Tzu‐Hsiu Tsai, James Chih‐Hsin Yang, Shang‐Gin Wu, Chia‐Lin Hsu, Min‐Shu Hsieh, Yen‐Lin Huang, Chia‐Ling Wu, Jin‐Yuan Shih
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Cancer Medicine
Subjects:
EGFR mutation
EGFR‐TKI resistance
next‐generation sequencing
NSCLC
Online Access:https://doi.org/10.1002/cam4.6870

Internet

https://doi.org/10.1002/cam4.6870

Similar Items